Phoenix Biotech Acquisition Corp. (PBAX) Stock
Phoenix Biotech Acquisition Corp. currently lacks substantial business operations.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Phoenix Biotech Acquisition Corp.
Phoenix Biotech Acquisition Corp. currently lacks substantial business operations. The company's primary objective is to complete a strategic business combination, such as a merger, asset acquisition, share exchange, or other form of reorganization, with one or more suitable enterprises. Its focus is on identifying and integrating with a firm engaged in the healthcare or healthcare-related industries within the United States or Europe. This entity was established in 2021 and maintains its headquarters in Oakland, California.
Phoenix Biotech Acquisition Corp. is headquartered in US.
Phoenix Biotech Acquisition Corp. (PBAX) stock trades at $5.85 with a market capitalization of $36.47M. The stock is valued at a price-to-earnings (P/E) ratio of -0.26, price-to-book of -18.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.12 and $12.80, and currently trades 54.3% below its 52-week high.
On profitability, Phoenix Biotech Acquisition Corp. generates a return on equity (ROE) of 1920.00% — well above the market average, a sign of a high-quality business, return on capital employed of 201.25%, an operating margin of 0.00%, a net profit margin of 0.00%.